MBRX
Moleculin Biotech, Inc.
Nasdaq · usd
Moleculin Biotech, Inc. (MBRX) trades at $7.03 (+8.15%) as of 1:49:11 PM EDT on Oct 26, 2026, -41.90% over the past month. Market cap is $6.63M, with 1.0 days to cover in short interest.
Stock performance
How Moleculin Biotech, Inc. (MBRX) stock has performed from one day to one year, with its 52-week range.
- 1D
- +7.54%
- 1W
- +31.89%
- 1M
- -41.90%
- YTD
- -89.44%
- 1Y
- -97.18%
- 52-wk range
- $3.23 – $315.00
Key statistics
Today's trading snapshot for MBRX: day range, open, previous close, volume and market cap.
- Day range
- $6.50 – $7.14
- Open
- $6.59
- Prev close
- $6.50
- Volume
- 10.32K
- Market cap
- $6.63M
- Shares out
- 1.02M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Moleculin Biotech, Inc.: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- —
- P/B
- 0.57
- P/FCF
- —
- ROE
- -280.7%
- ROA
- -154.2%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Oct 23, 2026
8-K filings
Material corporate events Moleculin Biotech, Inc. has disclosed to the SEC on Form 8-K.
- Charter amendmentOct 20, 2026
The stockholders of the Company approved an amendment to the Company's amended and restated certificate of incorporation... to effect the reverse stock split... The Amendment was filed with the Secretary of State of the State of Delaware.
- Investor presentationOct 16, 2026
On October 16, 2026, Moleculin Biotech, Inc. (the "Company") is using the attached presentation for its corporate presentation posted on the Company's website and is set forth as Exhibit 99.1 herein.
- Annual meeting resultsOct 9, 2026
The authorization to allow for the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes ... was approved. The votes on the matter were: Votes For 6,116,006; Votes Against 1,979,187; Abstain 151,896.
- Investor presentationOct 5, 2026
On October 5, 2026, Moleculin Biotech, Inc. (the "Company") is using the attached presentation for its corporate presentation posted on the Company's website and is set forth as Exhibit 99.1 herein.
- Business updateSep 29, 2026
With enrollment closed at 89 subjects, or potentially more, the Company remains on track for its planned comprehensive data readout of Part A in the first quarter of 2027.
Dividend history and stock splits
Moleculin Biotech, Inc.'s recent dividend payments and stock splits.
Dividends
No recent dividends.
Splits
- 1-for-20Oct 20, 2026
- 1-for-25Dec 1, 2025
- 1-for-15Mar 22, 2024
MBRX short interest
How heavily MBRX is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 1.0
- Short interest
- 204.58K
- Avg volume
- 1.71M
As of · reported to FINRA twice monthly.
MBRX news
The latest news and headlines about Moleculin Biotech, Inc. (MBRX).
- Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular MedicinepositiveGlobeNewswire Inc.· Sep 28, 2026
- Scalable Biotech Manufacturing Unlocks a $14B MarketpositiveBenzinga· Mar 27, 2026
- Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE StudypositiveGlobeNewswire Inc.· Mar 11, 2026
- Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsightpositiveGlobeNewswire Inc.· Dec 4, 2025
- Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)positiveGlobeNewswire Inc.· Jun 4, 2025
Frequently asked questions
What is the Moleculin Biotech, Inc. (MBRX) stock price today?
Moleculin Biotech, Inc. (MBRX) is trading at $7.03 (+8.15% on the day) as of 1:49:11 PM EDT on Oct 26, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Moleculin Biotech, Inc.?
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical…
What is the short interest in MBRX?
As of Sep 30, 2026, MBRX has 204.58K shares short and 1.0 days to cover.
What exchange is MBRX listed on?
Moleculin Biotech, Inc. (MBRX) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of MBRX with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a MBRX analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.